Mariner, LLC Nurix Therapeutics, Inc. Transaction History

Mariner, LLC

$55.8 Billion
Q3 2024

A detailed history of Mariner, LLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Mariner, LLC holds 31,795 shares of NRIX stock, worth $661,653. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,795

Previous 31,564 0.73%

Holding current value

$661,653

Previous $658,000 8.36%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$18.93 - $25.69 $4,372 - $5,934	231 Added 0.73%	31,795 $713,000
Q2 2024 Aug 13, 2024	BUY	$12.02 - $21.3 $144 - $255	12 Added 0.04%	31,564 $658,000
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $101 - $203	13 Added 0.04%	31,552 $463,000
Q4 2023 Feb 14, 2024	SELL	$4.25 - $10.71 $1,649 - $4,155	-388 Reduced 1.22%	31,539 $325,000
Q3 2023 Nov 13, 2023	SELL	$7.86 - $10.08 $6,122 - $7,852	-779 Reduced 2.38%	31,927 $250,000
Q2 2023 Aug 11, 2023	SELL	$8.7 - $13.28 $21,828 - $33,319	-2,509 Reduced 7.12%	32,706 $326,000
Q1 2023 May 12, 2023	BUY	$8.56 - $13.26 $41,190 - $63,807	4,812 Added 15.83%	35,215 $313,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $14.59 $3,914 - $5,792	397 Added 1.32%	30,403 $334,000
Q3 2022 Nov 10, 2022	BUY	$12.33 - $19.81 $1,343 - $2,159	109 Added 0.36%	30,006 $391,000
Q2 2022 Aug 15, 2022	BUY	$7.88 - $14.82 $6,091 - $11,455	773 Added 2.65%	29,897 $379,000
Q1 2022 May 13, 2022	BUY	$12.94 - $29.65 $1,371 - $3,142	106 Added 0.37%	29,124 $408,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $475 - $621	18 Added 0.06%	29,018 $840,000
Q3 2021 Nov 15, 2021	BUY	$22.71 - $36.69 $658,590 - $1.06 Million	29,000 New	29,000 $869,000

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $981M
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account